Abstract Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the United States after cancers of the lung and the breast and/or prostate. Whereas the incidence of CRC in the United States is among the highest in the world (approximately 52/100,000), its incidence in India is among the lowest (approximately 7/100,000), suggesting that lifestyle factors may be involved in development of the disease. Whereas obesity, excessive alcohol consumption, a high-calorie diet, and a lack of physical activity promote this cancer, evidence indicates that foods containing folates, selenium, vitamin D, dietary fiber, garlic, milk, calcium, spices, vegetables, and fruits are protective against CRC in humans. Numerous agents from "mother nature" (also called "nutraceuticals") that have potential to both prevent and treat CRC have been identified. The most significant discoveries relate to such compounds as cardamonin, celastrol, curcumin, deguelin, diosgenin, thymoquinone, tocotrienol, ursolic acid, and zerumbone. Unlike pharmaceutical drugs, these agents modulate multiple targets, including transcription factors, growth factors, tumor cell survival factors, inflammatory pathways, and invasion and angiogenesis linked closely to CRC. We describe the potential of these dietary agents to suppress the growth of human CRC cells in culture and to inhibit tumor growth in animal models. We also describe clinical trials in which these agents have been tested for efficacy in humans. Because of their safety and affordability, these nutraceuticals provide a novel opportunity for treatment of CRC, an "old age" disease with an "age old" solution.
Introduction
Colorectal cancer (CRC), the third most commonly diagnosed cancer in the United States, develops through a multistep process in which normal mucosa is first transformed into adenomatous polyps and then eventually into invasive carcinoma. CRC is a major cause of morbidity and mortality in the United States, with an estimated 143,460 new cases diagnosed and 51,690 deaths occurring in 2012 [1] . It is estimated that 5-10 % of all CRCs are because of inherited gene defects, but the great majority are sporadic with no heritable tendency. Lifestyle has been shown to be of major importance in the incidence of most cancers, especially CRC. Almost 70 % incidence of CRC, has been linked to diet, because some types of diet accelerate CRC whereas others prevent it. We will focus in this review on the dietary agents that have been implicated in preventing this cancer.
Irrespective of whether a cancer specifically results from a heritable mutation, extensive research within the last few years has indicated that most cancers are caused by dysregulation of as many as 500 gene products. These gene products include growth factors (e.g., EGF, VEGF, and IGF-1), growth factor receptors (e.g., EGF receptor), protein kinases (e.g., Src), inflammatory cytokines (e.g., TNF, IL-1, IL-6), inflammatory enzymes (e.g., COX-2, 5-LOX, PLA-2), proapoptotic proteins (e.g., TNF, Fas, TRAIL), antiapoptotic proteins (e.g., Bcl-2, Bcl-xL, cFLIP, IAP-1, IAP-2, survivin), tumor suppressors (e.g., p53, Rb), and transcription factors (e.g., NF-κB, AP-1, STAT3, HIF-1, PPARγ). Most of these gene products and the associated signaling pathways have been linked with CRCs. Perhaps one of the most important pathways in most CRCs is the pro-inflammatory pathway activated via the transcription factor NF-κB. This transcription factor has been shown to be activated by most risk factors linked to CRCs, including grilled meat, fried foods, saturated fatty acids, chemical and physical stress, and environmental pollutants [2] . Furthermore, constitutively active NF-κB has been encountered in most CRCs. Once activated, NF-κB regulates expression of gene products that mediate survival (e.g., antiapoptotic proteins Bcl-2, Bcl-xL, cFLIP, IAP-1, IAP-2, and survivin), proliferation (e.g., COX-2, c-myc, and cyclin D1), invasion (e.g., 5-LOX, MMP-9, ICAM-1, ELAM-1, and VCAM-1), and neo-angiogenesis (e.g., VEGF, IL-8, TNF, and IL-1) [3] . Most currently available agents that downregulate these pathways are highly specific for their targets (e.g., inhibitors of COX-2, VEGF, and EGFR). Such agents are unlikely to prevent diseases such as CRC which is caused by dysregulation of multiple gene products. Moreover, these agents are expensive and have numerous side effects [4, [5] [6] [7] . A multi-targeted approach is therefore required for both treatment and prevention. It is worth noting that the same molecular targets are used for both prevention and treatment [2, 8] .
The incidence of CRC in the United States (530 cases per million) is among the highest in the world. This contrasts with such regions as the Indian subcontinent (30 cases per million), in which CRC incidence is among the lowest in the world. Epidemiological and migration studies of Indians suggest that, to a large extent, these dramatic international differences in incidence can be explained by different environment, lifestyle, and diet. What is so unique about the Indian environment, lifestyle, and/or diet that CRC risk in India is disproportionately lower than in the United States? Given that food-derived compounds are constantly present in the intestine and may regulate the homeostasis of intestinal mucosa, one likely explanation is the nature of the Indian diet. On the basis of statistical and epidemiological data, Richard Doll and Richard Peto have postulated that 10-70 % (average 35 %) of human cancer mortality is attributable to diet [9] . Multiple lines of compelling evidence from epidemiological, clinical, and laboratory studies link cancer risk to nutritional factors. A feature of the Indian diet that distinguishes its from the Western diet is its higher proportion of dietary fiber, largely because of greater consumption of vegetarian food and lower intake of red meat than in a typical Western diet. However, the preponderance of evidence suggests that, after accounting for other dietary risk factors, high dietary fiber intake is not associated with a reduced risk of CRC [10] [11] [12] and, indeed, dietary fiber supplementation failed to reduce the risk of recurrence of colorectal adenomas in multiple randomized trials [13] [14] [15] [16] . An alternative hypothesis is that distinctive spices routinely used in Indian cuisine confer protection against CRC. Evidence from multiple laboratories indicates that spices prevent CRC development by modulating proinflammatory pathways closely linked with tumorigenesis.
Effect of Nutraceuticals in Cancer Prevention
The use of plant-derived products (also called dietary botanicals) for the welfare of humankind extends back as far as recorded history. The quest for plants, parts of plants, and components of parts of plants, that confer health benefits has perennially inspired human curiosity. At one time, the major source of medicine was the plants consumed by humansprompting Hippocrates to preach, almost 25 centuries ago, "let food be thy medicine and medicine be thy food." This adage also calls to mind the common saying, "we are what we eat". This philosophy is consistent with the position of both the National Cancer Institute and the American Cancer Society that eating more fruit and vegetables daily can reduce an individual's risk of developing cancer. However, accurate determination of the precise mechanisms by which the components of fruit and vegetables prevent cancer is needed before their inclusion in dietary supplements or evaluation in prospective clinical trials can be recommended. It is estimated that over 70 % of cancers are preventable, with dietary agents making a 35 % contribution. It remains unclear what specific dietary agents or nutraceuticals can prevent cancer. It is notable that more than half of all drugs approved by the Food and Drug Administration for cancer therapy within the last four decades have been either natural products, natural product derivatives, compounds based on natural products, or mimics of natural products [17] ; indeed, cancer chemoprevention with botanicals is increasingly recognized as a promising research strategy [18] . In this review, we show that that numerous nutraceuticals have potential as treatments for CRC (Tables 1, 2 and 3) . These include acetoxychavicol acetate, anacardic acid, berberine, betulinic acid, boswellic acid, butein, camptothecin, capsaicin, caffeic acid phenethyl ester, cardamonin, celastrol, coronarin, curcumin, deguelin, diosgenin, elephantopin, emodine, embelin, escin, fisetin, flavopiridol, flavonoids, gambogic acid, garcinol, gossypol, gossypin, guggulsterone, indole-3-carbinol, morin, naphthoquinone, nimbolide, noscapine, oleandrin, piperine, piceatannol, pinitol, plumbagin, pomegranate, retinoids, honokiol, sanguinarine, sesamin, silymarin, simvastatin, terpenoid, thymoquinone, tocotrienol, triptolide, ursolic acid, withanolides, xanthohumol, and zerumbone. The different molecular targets modulated by these nutraceuticals β-catenin, Wnt-1, cyclin D1, c-jun, MMP-7 [131] are shown in Table 1 . These targets include growth factors and their receptors, protein kinases, inflammatory biomarkers, and a variety of transcription factors. Biomarkers that are downregulated by nutraceuticals are shown in Fig. 1 . Those that are upregulated are shown in Fig. 2 .
Use of these nutraceuticals for both prevention (Table 2) and treatment (Table 3 ) of CRC can be envisaged. Modulation of biomarkers has been observed not only in colon cancer cells in culture but also in animal models of CRC (Tables 2 and 3) . IL-1α, IL-1β, IL-6, TNFα [150] ABCG2, ATP-binding cassette sub-family G member 2; ACC, acetyl-CoA carboxylase; AKBA, acetyl-keto-beta-boswellic acid; AMPK, AMPactivated protein kinase; AR, aldose reductase; ARNT, aryl hydrocarbon receptor nuclear translocator; Bag-1, Bcl-2-binding protein; CAPE, caffeic acid phenethyl ester; CBR3, Carbonyl reductase 3; CDDO, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid; CDK, cyclin dependent kinase; CHOP, CCAAT/enhancer-binding protein-homologous protein; COX-2, cyclooxygenase-2; CXCR4, cysteine X cysteine (CXC) chemokine receptor 4; DcR, decoy receptor; DR, death Receptor; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinases; FAK, focal adhesion kinase; GPx, glutathione peroxidase; GR, glucocorticoid receptor; GRP, glucose-regulated protein; GSH, glutathione; GSK-3β, glycogen synthase kinase-3β; GST, glutathione S-transferase; HO-1, hemoxygenase-1; ICAM, intracellular cell adhesion molecule; IDPm, NADP(+)-dependent isocitrate dehydrogenase; IFN, interferon; IGF, insulin-like growth factor; IL, interleukin; iNOS, inducible nitric oxide synthase; I.Bα, inhibitor of kappaB alpha; KLF, Krüppel-like factor; KLF4, Krüppel-like factor 4; LC3, microtubule-associated protein 1 light chain 3; MAPK, mitogen-activated protein kinase; MMP, matrix metalloproteinase; NF-.B, nuclear factor-kappaB; NQO1, quinone oxidoreductase 1; Nrf2, NF-E2-related factor 2; PCNA, proliferating cell nuclear antigen; PGE2, prostaglandin E2; Pgp (or P-gp), P-glycoprotein; PI3K, phosphatidylinositol-3-kinase; PP2Ac, protein phosphatase 2Ac subunit; PPARγ, peroxisome proliferator-activated receptor gamma; PRL-3, phosphatase of regenerating liver-3; PTC, Primary tumor cells of colon adenocarcinoma; PTTG, pituitary tumor transforming gene; QR, quinone reductase; SOD, superoxide dismutase; STAT3, signal transducers and activators of transcription 3; TNF, tumor necrotic factor; tNOX, tumor-associated NADH oxidase; TRAIL, TNF related apoptosis-inducing ligand; VDRE, vitamin D responsive element; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; XIAP, X-linked inhibitor of apoptosis. 5-LOX, 5-lipoxygenase; ALDH, aldehyde dehydrogenase; cFLIP, cellular FADD-like interleukin-1 beta-converting enzyme (FLICE) inhibitory protein; CHEK1, checkpoint kinase 1; Chk2, checkpoint kinase 2; c-IAP1, cellular inhibitor of apoptosis 1; FADD, Fas-associated protein with death domain; FasL, Fas ligand; HDAC2, histone deacetylase 2; I-FLICE, inhibitor of FLICE; JNK, c-Jun N-terminal kinase; LDH, lactose dehydrogenase; MDR1, multidrug resistance protein 1; mTOR, mammalian target of rapamycin; PDCD4, programmed cell death 4;TGFβR, transforming growth factor beta receptor; tGPx, total GPx; TLR-4, Toll-like receptor-4; TRPV6, Transient receptor potential cation channel subfamily V member 6; UGT, UDP-glucuronosyltransferase; XBP1, Xbox binding protein 1
Effect of Nutraceuticals in CRC Prevention
There are numerous reasons to conclude that most cancers, and CRCs in particular, are preventable. First, CRCs are more common in developed countries than in developing countries Noscapine β-Catenin, cyclin D1, c-myc, p21 [173] AMPK, AMP-activated protein kinase; AR, aldose reductase; COX-2, cyclooxygenase-2; GPx, glutathione peroxidase; GST, glutathione Stransferase; ERK, extracellular signal-regulated kinases; HO-1, hemoxygenase-1; HMG-CoA reductase, 3-hydroxy-3-methyl-glutaryl-CoA reductase; HSP, heat shock proteins; NF-κB, nuclear factor-kappaB; IFN, interferon; IL, interleukin; iNOS, inducible nitric oxide synthase; MMP, matrix metalloproteinase; Nrf2, NF-E2-related factor 2; PCNA, proliferating cell nuclear antigen; QR, quinone reductase; SOD, superoxide dismutase; STAT3, signal transducers and activators of transcription 3; TNF, Tumor necrotic factor; VEGF, vascular endothelial growth factor
Curcumin's mechanism of action has been studied extensively [179] . Our group showed that curcumin downregulated activation of NF-κB [180] , thus leading to downregulation of the expression of anti-apoptotic, cell-proliferative, invasive, and angiogenic gene products [181] . In addition to downregulating NF-κB activation, curcumin can suppress activation of STAT3 [182] , HIF-1 [183] , and PPARγ [184] . Curcumin also downregulates the activity and expression of both cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) [185] , and the expression of TNF, IL-1, and IL-6. It also inhibits both the anti-apoptotic activating transcription factor [186] and EGF receptor signaling [187] . Despite interfering with all of these targets, curcumin has been found to be relatively safe pharmacologically at very high doses [188] . Moreover, no dose-limiting toxicity has been established in previously published clinical trials.
Although curcumin is active against CRC in a variety of preclinical models, it has several limitations. First and foremost, its bioavailability and tissue distribution are very poor [189] , although piperine, a component of Piper nigrum that is often consumed with turmeric, has been shown to enhance the bioavailability of curcumin [190] . Second, it is not COX-2, cyclooxygenase-2; EGFR, Epidermal growth factor receptor; ERK, extracellular signal-regulated kinases; GSK-3β, Glycogen synthase kinase-3β; NF-κB, nuclear factor-kappaB; ICAM, intracellular cell adhesion molecule; iNOS, inducible nitric oxide synthase; MMP, matrix metalloproteinase; PCNA, proliferating cell nuclear antigen; VEGF, vascular endothelial growth factor curcumin but turmeric that is consumed routinely by people in the Indian subcontinent where the incidence of CRC is relatively low. Third, people consuming turmeric do not consume turmeric alone but rather in combination with other spices such as Piper nigrum (black pepper) and Zingiber officinale (ginger). Fourth, turmeric has activity that is different from those of curcumin [191, 192] . Fifth, the activity of curcumin is potentiated by turmerones and other minor components of turmeric [193] . For all of these reasons, further in-depth investigation of turmeric is warranted.
[6]-Gingerol Ginger, the rhizome of Zingiber officinale, is as reputed for its medicinal properties as is turmeric. Ginger has traditionally been used in different parts of the world for a variety of human ailments and, in particular, to aid digestion and treat nausea and vomiting in pregnancy [194] . Some pungent constituents present in ginger and other zingiberaceous plants have potent antioxidant, anti-inflammatory, antiemetic, antiulcer, cardiotonic, antihypertensive, hypoglycemic, antihyperlipidemic, and immuno-stimulant properties. Some of these constituents also had cancer-preventive activity in experimental studies and clinical trials [195, 196] . These properties of ginger are attributed to the presence of pungent vallinoids, specifically [6] -gingerol and [6]-paradol, and to such other constituents as shogaols and zingerone. Experimental studies have also revealed that ginger and its most active constituent, [6] -gingerol, regulate the molecules in cellular signal transduction pathways, including NF-κB, AP-1, growth factors, chemokines, MAPK, p53, cyclin D1, VEGF, COX-2, and iNOS pathways [197] [198] [199] [200] [201] [202] [203] .
By modulating multiple cell signaling pathways, these components inhibit cancer development and/or progression. Both [6] -gingerol and [6]-paradol have been found to induce cancer cell apoptosis [204] .
[6]-Gingerol has also been shown to inhibit phorbol ester-induced inflammation, epidermal ornithine decarboxylase activity, and skin tumor promotion in mice [205] . Specifically in CRC, [6] -gingerol has been shown to reduce the incidence of CRCs in a rat azoxymethane (AOM) model [206] , and to inhibit CRC cell proliferation, endothelial cell tube formation [207] , and G1 cell cycle arrest. [6] -Gingerol inhibits these processes by downregulation of cyclin D1 via inhibition of β-catenin translocation [201] . [6] -Shogaol has been shown to induce apoptosis via reactive oxygen species (ROS) production, caspase activation, and GADD153 expression [208] . The chemopreventive properties of both ginger and turmeric have been linked in part to the upregulation of MAP kinase phosphatase-5 [209] . Ginger thus seems to contain a variety of constituents that may ultimately be of use in cancer prevention and treatment.
Piperine
Black pepper (Piper nigrum), a native Indian botanical, has been used in Indian cooking for centuries. It is valued for its distinctive sharp, stinging quality, which has been attributed to its active ingredient, the alkaloid piperine. Since the discovery of Piper nigrum's active ingredient piperine, use of black pepper has captivated the interest of modern medical researchers. Many physiological effects of Piper nigrum, its extracts, or its bioactive compound piperine, have been reported in recent decades. By stimulating the digestive enzymes of the pancreas, piperine enhances digestive capacity and significantly reduces gastrointestinal transit time for food [210] . Piperine has been shown to enhance the bioavailability of a number of therapeutic drugs and phytochemicals by inhibition of enzymatic drug biotransforming reactions in the liver and intestine [211] . Piperine strongly inhibits the activity of hepatic and intestinal aryl hydrocarbon hydroxylase and uridine dinucleotide phosphate-glucuronyl transferase [211] . Most clinical studies on piperine have focused on its effect on drug metabolism as a means of improving the bioavailability of other botanicals [189, 212, 213] . Piperine's bioavailabilityenhancing property is also partly attributed to increased absorption caused by its effect on the ultrastructure of the intestinal brush border [214, 215] . Piperine has been demonstrated, in in-vitro studies, to protect against oxidative damage by inhibiting or quenching ROS. Piper nigrum or piperine treatment has also been found to reduce lipid peroxidation in-vivo and beneficially affect antioxidant status in several experiments involving oxidative stress [215, 216] .
1′-Acetoxychavicol Acetate
1′-Acetoxychavicol acetate (ACA), which is obtained from the rhizomes of Alpinia galanga, is a component of traditional Asian condiments. It has both chemopreventive and chemotherapeutic potential in animals and in in-vitro models of CRC. ACA has been shown to induce apoptosis in CRC cell lines. It has also been reported that ACA inhibits DNA synthesis, thereby inhibiting cell proliferation [217] . In rat intestine epithelial cells (IEC6), ACA promoted glutathione S-transferase (GST) and NAD(P)H:quinone oxidoreductase 1 activity, increased intracellular glutathione levels, and upregulated intranuclear Nrf2 and cytosolic p21 [19] . It also has the ability to inhibit AOM-induced colon tumorigenesis in rats [151] . Feeding these rats with ACA significantly reduced the incidence of colon carcinoma by suppressing such proliferation biomarkers as ornithine decarboxylase activity and colonic mucosal polyamine content. Such inhibition was also associated with elevated levels of activity of phase II enzymes, including GST and QR, in the rat colon [151] .
Berberine
Berberine is an isoquinoline natural alkaloid found in the roots, rhizomes, stems, and bark of a wide variety of traditional herbs, including goldenseal, barberry, and Oregon grape. Numerous studies have shown that it can prevent and treat CRC. In in-vitro assay, berberine inhibited proliferation and induced apoptosis of a variety of CRC cells. It induced cell cycle arrest at the G2/M phase and caused apoptosis, as evidenced by loss of mitochondrial membrane potential, release of cytochrome c, suppression of c-IAP1, Bcl-2, and Bcl-xL, induction of p21 expression, activation of caspases, and cleavage of PARP [20, 22] . In addition, berberine-induced apoptosis was accompanied by phosphorylation of JNK and p38 MAPK, increases in FasL and t-BID levels, and ROS generation [22] . Berberine's antiproliferative and apoptotic activity has been found to be associated with inhibition of NF-κB and Wnt/β-catenin signaling pathways [20, 152] . Moreover, berberine modulated pgp-170 expression in cancer cells, which was associated with changes in drug resistance [25] and inhibition of arylamine N-acetyltransferase activity in a human colon tumor cell line [218] . In an AOM-induced colon carcinogenesis rat model, berberine significantly inhibited increases in lipid peroxidation and protein bound carbohydrates, and enhanced antioxidative status [153] . Oral administration of berberine was also found to inhibit COX-2 activity, without inhibiting COX-1 activity, in AOM-induced rat colon carcinogenesis [154] . Thus, berberine inhibits neoplastic transformation in rat colon.
Whole Botanical is Better than a Single Active Principle
Whether genistein, lycopenes, statins, catechins, or resveratrol, evidence indicates that the original sources of these nutraceuticals (soy, tomato, red yeast rice, green tea, and red grapes, respectively) may have in-vivo activity superior to that of their isolated active components. Indeed, numerous lines of evidence suggest that the whole botanical may be better than its active principle. For instance, Curcuma longa contains curcumin, demethoxycurcumin (DMC), bisdemethoxycurcumin (BDMC), turmeric oil (also known as turmerones), cyclocurcumin, and other constituents. Although curcumin is a major constituent (2-6 %) of Curcuma longa, other components occur in minor but significant amounts. Curcuma longa oil consists of aromatic turmerone (ar-turmerone), α-turmerone, and β-turmerone. Curcuma longa oil has been linked with antifungal [219, 220] , antibacterial [221] , insecticidal [222] , mosquitocidal [223] , antioxidant [224] , antimutagenic [224] , and anticancer [225] activity. This oil has also been found to inhibit oral submucous fibrosis, a precancerous condition for oral cancer in healthy volunteers [225] . Turmeric oil has also been shown to enhance the bioavailability of curcumin in human volunteers [193, 226] . Synergy has been observed between curcumin, DMC, and BDMC. Specifically, it has been shown that the ability of curcumin to inhibit peroxidation of linoleic acid by 15-lipoxygenase is synergistically enhanced by DMC and BDMC. Furthermore, we have shown that the antiinflammatory activity of curcumin is enhanced when curcumin is combined with DMC and BDMC [227] . Similarly, the nematocidal activity of turmeric has been reported to be higher than that of curcumin alone [228] . Curcumin-free aqueous turmeric extracts have been shown to suppress 7,12-dimethylbenz[α]anthracene (DMBA)-induced rat mammary tumor formation [192] and to inhibit benzo[a]pyrene-induced forestomach papillomas in mice [191] . Consistent with evidence that a whole botanical may potentially be more effective than its active principle, there is also an evolving body of evidence to suggest that whole botanicals have potent antitumor activity at clinically meaningful doses. Reports indicate that turmeric alone blocks glucuronidation and sulfation in Caco-2 cells invitro [229] , inhibits early activation of the Epstein-Barr-virus antigen [230] , inhibits benzo[a]pyrene-derived DNA adduct formation [231] , and suppresses the growth of Helicobacter pylori [232] . In rodents, 1 % dietary turmeric was found to inhibit DMBA-induced carcinogenesis [233] , abrogate croton oil-induced skin tumor formation [234] , and suppress nitrosodiethylamine-induced hepatocarcinogenesis [235] . In addition, turmeric was found to prevent benzo[a]pyrene-induced forestomach tumors in Swiss mice and methyl(acetoxymethyl)nitrosamine-induced oral mucosal tumors in Syrian golden hamsters [236] . In a study of DMBA-induced mammary tumorigenesis in C3H (Jax) mice and Wistar rats, dietary turmeric suppressed mammary tumor virus-related reverse transcriptase activity, abrogated preneoplastic changes in the mammary glands, and reduced tumor incidence and tumor burden [237] .
Combination of Botanicals is Expected to be Superior to a Single Botanical Alone
There is much interest in evaluating the likelihood that a combination of crucial botanicals might exhibit synergistic protective activity against CRC. A wide variety of botanicals and their phenolic compounds and flavonoids have potent antioxidant, antimutagenic, and anticarcinogenic activity. Several studies have suggested that a combination of botanicals and/or their active principles might be more efficacious than any one botanical alone. Piperine has been shown to enhance the bioavailability of curcumin in rodents and humans, in part by inhibition of glucuronidation [190] . We have also confirmed that piperine enhances the bioavailability of curcumin in human subjects [189] . In one study testing this combination, oral curcumin with piperine reversed lipid peroxidation in patients with tropical pancreatitis [212] . In another study, combination of piperine with curcumin significantly enhanced anti-immobility, neurotransmitter-enhancing (serotonin and dopamine) and monoamine oxidase inhibitory effects compared with curcumin alone [213] . When 5-lipoxygenase, the crucial enzyme involved in biosynthesis of leukotrienes, was evaluated in human polymorphonuclear leucocytes, the order of inhibitory activity was noted to be quercetin > eugenol > curcumin > cinnamaldehyde > piperine > capsaicin > allyl sulfide [238] . Furthermore, the inhibitory potency of aqueous extracts of these botanicals correlated with the active principles of their respective botanicals, with the combination of active principles or extracts synergistically inhibiting 5-LOX activity [238] .
Human Studies
Clinical trials of nutraceuticals for CRC prevention and treatment in humans have established more knowledge about curcumin than about all other nutraceuticals. This agent has been examined for patients with ulcerative colitis (UC) and Crohn's disease (CD) [239] . In an open-label study, curcumin was administered to five patients with ulcerative proctitis and five with CD. All proctitis patients improved, with reductions in concomitant medications in four, and four of five CD patients had reduced Crohn's Disease Activity Index scores and sedimentation rates. Curcumin was also examined in a randomized, multicenter, double-blind, placebo-controlled trial of maintenance therapy for UC [240] . Eighty-nine patients with quiescent UC were recruited. Forty-five patients received curcumin (1 g after breakfast and 1 g after the evening meal) plus sulfasalazine or mesalamine for six months, and 44 patients received placebo plus sulfasalazine or mesalamine for six months. Clinical activity index and endoscopic index were determined at entry, then every two months, at the conclusion of the six-month trial, and at the end of six-month follow-up. Of 43 patients who received curcumin, two relapsed during six months of therapy whereas eight of 39 patients in the placebo group relapsed. These results were indicative of a significant difference between curcumin and placebo. Furthermore, curcumin improved both the clinical activity index and endoscopic index levels in patients, thus suppressing the morbidity associated with UC. A six-month follow-up was conducted during which patients in both groups were on sulfasalazine or mesalamine. Eight additional patients in the curcumin group and six patients in the placebo group relapsed.
Familial adenomatous polyposis is an autosomal-dominant disorder characterized by the development of hundreds of colorectal adenomas and eventual colorectal cancer. Regression of adenomas in this syndrome occurs on administration of nonsteroidal anti-inflammatory drugs and COX-2 inhibitors, both of which can have major side effects. Curcumin was examined in combination with quercetin for FAP patients [177] . Five FAP patients with previous colectomy received curcumin 480 mg and quercetin 20 mg orally three times a day. All five patients' polyps had decreased in number and size from baseline after a mean of six months of treatment with curcumin and quercetin. The mean percentage decreases in the number and size of polyps from baseline were 60.4 % and 50.9 %, respectively.
Recently, Carroll and colleagues trialed the use of curcumin for prevention of colorectal neoplasia [241] . The group examined the effects of oral curcumin (2 g or 4 g per day for 30 days) on prostaglandin E2 (PGE 2 ) within aberrant crypt foci (ACF; primary endpoint), 5-HETE, ACF number, and proliferation in a non-randomized, open-label clinical trial with 44 eligible smokers with eight or more ACF on screening colonoscopy. Forty-one subjects completed the study. A significant reduction (40 %) in patients' ACF numbers occurred in the 4 g dose group, whereas ACF numbers were not reduced in the 2 g dose group. Interestingly, neither dose of curcumin reduced PGE 2 or 5-HETE within ACF or normal mucosa or reduced Ki-67 in normal mucosa.
Numerous studies have also been conducted on use of curcumin for treatment of CRC. A dose-escalation study with healthy volunteers revealed insignificant serum levels of curcumin even when as much as 12,000 mg curcumin was consumed daily [188] . Sharma et al. examined the pharmacodynamic and pharmacokinetic properties of oral curcumin in patients with CRC [242] . Interestingly, they showed that daily ingestion of 440 mg curcumin for 29 days (15 patients) was accompanied by a 59 % decrease in lymphocytic glutathione S-transferase activity, but this was not observed for a higher dose (2,200 mg). Another study [243] showed that a daily dose of 3.6 g curcumin on days 1 and 29 caused 62 % and 57 % decreases, respectively, in inducible PGE 2 production in blood samples taken 1 h after dose administration compared with levels observed immediately predose. Garcea et al. [244] found that administration of curcumin (3,600 mg) reduced DNA adduct 3-(2-deoxy-beta-di-erythro-pentafuranosyl)-pyr[1,2-alpha]-purin-10(3H)one M(1)G levels in malignant colorectal tissue from 4.8±2.9 adducts per 107 nucleotides to 2.0±1.8 adducts per 107 nucleotides. COX-2 protein levels in malignant colorectal tissue were not affected by curcumin. In another study, 106 colorectal cancer patients were given 360 mg curcumin orally three times a day and were then monitored for cancer-induced weight loss, serum TNF levels, tumor cell apoptosis, and other biomarkers on days 10, 20, and 30 after treatment [245] . The authors showed that curcumin administration increased body weight, reduced serum TNF-α levels, increased numbers of apoptotic tumor cells, enhanced the expression of p53 molecules in tumor tissue, and modulated tumor cell apoptotic pathways, as indicated by upregulation of Bax and downregulation of Bcl-2. They concluded that curcumin treatment improves the general health of patients. All these studies therefore indicate that curcumin is quite safe when consumed in large quantities. Paradoxically, however, its effect in patients is unrelated to serum levels. Lower doses also seem to be more effective than higher doses in modulating biomarkers in human subjects.
Conclusion
This review clearly shows that a variety of nutraceuticals provided by Mother Nature have huge potential for both prevention and treatment of CRC. However, more clinical trials are required to prove neutraceuticals' potential against this highly lethal disease. Because these agents can be administered chronically without any concern for safety and are highly affordable, their use has been the wave of the past and is likely to continue as the wave of the future. 
